121 related articles for article (PubMed ID: 20392095)
21. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors.
Yap JL; Cao X; Vanommeslaeghe K; Jung KY; Peddaboina C; Wilder PT; Nan A; MacKerell AD; Smythe WR; Fletcher S
Org Biomol Chem; 2012 Apr; 10(15):2928-33. PubMed ID: 22395339
[TBL] [Abstract][Full Text] [Related]
22. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN
Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642
[TBL] [Abstract][Full Text] [Related]
23. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
Vo DD; Gautier F; Juin P; Grée R
Eur J Med Chem; 2012 May; 51():286-93. PubMed ID: 22425031
[TBL] [Abstract][Full Text] [Related]
25. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein.
Tan YX; Tan TH; Lee MJ; Tham PY; Gunalan V; Druce J; Birch C; Catton M; Fu NY; Yu VC; Tan YJ
J Virol; 2007 Jun; 81(12):6346-55. PubMed ID: 17428862
[TBL] [Abstract][Full Text] [Related]
26. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein.
Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D
Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970
[TBL] [Abstract][Full Text] [Related]
27. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
Kvansakul M; Yang H; Fairlie WD; Czabotar PE; Fischer SF; Perugini MA; Huang DC; Colman PM
Cell Death Differ; 2008 Oct; 15(10):1564-71. PubMed ID: 18551131
[TBL] [Abstract][Full Text] [Related]
28. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
[TBL] [Abstract][Full Text] [Related]
29. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Tang Y; Zhang DY; Wu XM
Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
[TBL] [Abstract][Full Text] [Related]
30. Targeting Bcl-X(L) for prevention and therapy of skin cancer.
Zhang J; Bowden GT
Mol Carcinog; 2007 Aug; 46(8):665-70. PubMed ID: 17443741
[TBL] [Abstract][Full Text] [Related]
31. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
33. Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone.
Palmeira A; Paiva A; Sousa E; Seca H; Almeida GM; Lima RT; Fernandes MX; Pinto M; Vasconcelos MH
Chem Biol Drug Des; 2010 Jul; 76(1):43-58. PubMed ID: 20456373
[TBL] [Abstract][Full Text] [Related]
34. Oral disinfectants inhibit protein-protein interactions mediated by the anti-apoptotic protein Bcl-xL and induce apoptosis in human oral tumor cells.
Gräber M; Hell M; Gröst C; Friberg A; Sperl B; Sattler M; Berg T
Angew Chem Int Ed Engl; 2013 Apr; 52(16):4487-91. PubMed ID: 23512547
[No Abstract] [Full Text] [Related]
35. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.
Shangary S; Johnson DE
Leukemia; 2003 Aug; 17(8):1470-81. PubMed ID: 12886234
[TBL] [Abstract][Full Text] [Related]
36. Amyloid fibrils formed by the programmed cell death regulator Bcl-xL.
Chenal A; Vendrely C; Vitrac H; Karst JC; Gonneaud A; Blanchet CE; Pichard S; Garcia E; Salin B; Catty P; Gillet D; Hussy N; Marquette C; Almunia C; Forge V
J Mol Biol; 2012 Jan; 415(3):584-99. PubMed ID: 22119486
[TBL] [Abstract][Full Text] [Related]
37. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
38. Structure-based discovery of a new class of Bcl-xL antagonists.
Rega MF; Leone M; Jung D; Cotton NJ; Stebbins JL; Pellecchia M
Bioorg Chem; 2007 Aug; 35(4):344-53. PubMed ID: 17512966
[TBL] [Abstract][Full Text] [Related]
39. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.
Perez HL; Banfi P; Bertrand J; Cai ZW; Grebinski JW; Kim K; Lippy J; Modugno M; Naglich J; Schmidt RJ; Tebben A; Vianello P; Wei DD; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3946-50. PubMed ID: 22608961
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of the BH3-Only Protein Binding Interface of Bcl-xL.
Liu X; Beugelsdijk A; Chen J
Biophys J; 2015 Sep; 109(5):1049-57. PubMed ID: 26331262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
